TABLE 1.
Baseline characteristics of the study population.
| All (n = 169) |
No clinical events (n = 125) |
Experienced clinical events (n = 44) |
P-value | |
| Age, years | 55.4 ± 14.6 | 54.9 ± 15.3 | 56.6 ± 12.5 | 0.511 |
| Male sex, n (%) | 88 (52.1) | 63 (50.4) | 25 (56.8) | 0.577 |
| Body mass index, kg/m2 | 22.7 ± 3.0 | 22.6 ± 2.9 | 23.1 ± 3.1 | 0.355 |
| Hypertension, n (%) | 62 (36.7) | 42 (33.6) | 20 (45.5) | 0.222 |
| Diabetes mellitus, n (%) | 12 (7.1) | 7 (5.6) | 5 (11.4) | 0.348 |
| Chronic kidney disease, n (%) | 20 (11.8) | 11 (8.8) | 9 (20.5) | 0.074 |
| Coronary artery disease, n (%) | 28 (16.6) | 18 (14.4) | 10 (22.7) | 0.297 |
| Atrial fibrillation, n (%) | 60 (35.5) | 36 (28.8) | 24 (54.5) | 0.004 |
| Charlson comorbidity index | 1 (0-2) | 1 (0-2) | 1 (0-2) | 0.762 |
| Hemoglobin, g/dL | 13.3 ± 2.7 | 13.5 ± 1.7 | 12.0 ± 2.6 | 0.003 |
| Creatinine, mg/dL | 1.0 ± 0.5 | 0.9 ± 0.5 | 1.1 ± 0.4 | 0.097 |
| eGFR, ml/min/1.73 m2 | 83.1 ± 24.6 | 86.8 ± 23.4 | 73.3 ± 25.5 | 0.005 |
| MR etiology before repair, n (%) | 0.994 | |||
| Rheumatic | 12 (7.1) | 9 (7.2) | 3 (6.8) | |
| Prolapse | 149 (88.2) | 110 (88.0) | 39 (88.6) | |
| Other | 8 (4.7) | 6 (4.8) | 2 (4.5) | |
| Device used for MV repair, n (%) | 0.887 | |||
| C-ring | 107 (63.3) | 81 (64.8) | 26 (59.1) | |
| D-ring | 39 (23.1) | 27 (21.6) | 12 (27.3) | |
| Restrictive ring | 23 (13.6) | 17 (13.6) | 6 (13.6) | |
| Residual significant MR | 75 (44.4) | 61 (48.8) | 14 (31.8) | 0.076 |
eGFR, estimated glomerular filtration rate; MR, mitral regurgitation; MV, mitral valve.